Loading...
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham, D Hawkes, E Jack, A Qian, W Smith, P Mouncey, P Pocock, C Ardeshna, K Radford, John A McMillan, A
Cunningham, D
Hawkes, E
Jack, A
Qian, W
Smith, P
Mouncey, P
Pocock, C
Ardeshna, K
Radford, John A
McMillan, A
Citations
Altmetric:
Abstract
Dose intensification with a combination of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) every 2 weeks improves outcomes in patients older than 60 years with diffuse large B-cell lymphoma compared with CHOP every 3 weeks. We investigated whether this survival benefit from dose intensification persists in the presence of rituximab (R-CHOP) in all age groups.
Description
Date
2013-05-25
Publisher
Collections
Files
Loading...
From CORE (MUCC)
Adobe PDF, 429.22 KB
Keywords
Type
Article
Citation
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. 2013, 381 (9880):1817-26 Lancet